Rifampicin induced thrombocytopenia in daily antituberculous regimen treatment
DOI:
https://doi.org/10.15381/anales.v71i2.85Keywords:
Thrombocytopenia, rifampin, tuberculosis, pulmonary, drug effects.Abstract
We present the case of a 31 year-old patient with the diagnosis of lung tuberculosis by lung X-ray and positive acid alcohol resistant bacillus in sputum, who after 10 days of oral treatment with isoniazid, ethambutol, pyrazinamide and rifampicin (RFP), developed severe hemorrhagic manifestations associated with severe thrombocytopenia (2 000/mL) and slight right body hemiparesis. There was complete normalization of platelet count and motor function five days after suspension of the four drugs. We decided to re-expose the patient sequentially to the four drugs and after 12 hours of receiving RFP again developed severe thrombocytopenia (2 000/mL) not occurring with the other three drugs, and normalized completely after 36 hours of drug suspension. Later on, the addition of parenteral streptomycin successfully completed the treatment. The current case demonstrates a not very frequent adverse effect of a first line drug for the treatment of tuberculosis, which should be considered as a very serious complication and whose management should include the immediate and indefinite suspension of the drug in the affected patient, because of the high likelihood of having the same response every time he is challenged during his life.Downloads
Published
2010-06-14
Issue
Section
Casos clínicos
License
Copyright (c) 2010 Victor Mechan, Wuili Valqui, Luis Vilchez, José Castro, Fiorella Lipari
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Those authors who have publications with this magazine accept the following terms:
- Authors will retain their copyrights and guarantee the journal the right of first publication of their work, which will be simultaneously subject to Creative Commons Attribution License that allows third parties to share the work as long as its author and its first publication this magazine are indicated.
- Authors may adopt other non-exclusive licensing agreements for the distribution of the version of the published work (eg, deposit it in an institutional electronic file or publish it in a monographic volume) provided that the initial publication in this magazine is indicated.
- Authors are allowed and recommended to disseminate their work over the Internet (eg: in institutional telematic archives or on their website) before and during the submission process, which It can produce interesting exchanges and increase quotes from the published work. (See El efecto del acceso abierto ).
How to Cite
1.
Mechan V, Valqui W, Vilchez L, Castro J, Lipari F. Rifampicin induced thrombocytopenia in daily antituberculous regimen treatment. An Fac med [Internet]. 2010 Jun. 14 [cited 2024 Jul. 17];71(2):132-4. Available from: https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/85